Pipeline innovation bodes well for systemic lupus erythematosus market
While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab) and off-label Rituxan (rituximab, from Roche [ROG: SIX]), new emerging entrants, which appear to offer significant therapeutic benefits, will cause dramatic changes to the future SLE biological treatment market landscape.
According to a new report from business intelligence provider GBI Research, there are extensive research efforts into innovative biologic programs in the SLE pipeline, which target a wide range of cytokines modulators, as well as including cellular targets of the immune system. In fact, cytokine modulators now constitute the largest proportion (33%) of all active pipeline programs for SLE.
LymphoCide and Lupuzor likely to come to market with next decade
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze